中国神经再生研究(英文版) ›› 2014, Vol. 9 ›› Issue (9): 909-911.doi: 10.4103/1673-5374.133131

• 观点:神经损伤修复保护与再生 • 上一篇    下一篇

皮质类固醇如何影响中枢神经系统的髓鞘发生?

  

  • 收稿日期:2014-05-13 出版日期:2014-05-20 发布日期:2014-05-20

How do corticosteroids influence myelin genesis in the central nervous system?

Divya M. Chari   

  • Received:2014-05-13 Online:2014-05-20 Published:2014-05-20
  • Contact: Divya M. Chari, Cellular and Neural Engineering Group, Institute for Science and Technology in Medicine, School of Medicine, Keele University, Keele, Staffordshire, ST5 5BG, UK, d.chari@keele.ac.uk.
  • Supported by:

    This work was funded through grants from the British Neuropathological Society, North Staffordshire Medical Institute and University of Nottingham.

摘要:

大剂量免疫抑制剂皮质类固醇疗法已被广泛应用于多发性硬化症和脊髓损伤的临床治疗当中。然而,有一些报道也指出了皮质类固醇治疗会影响神经功能,如延缓轴突周围的新髓鞘产生以及髓鞘再生等。来自英国基尔大学医学院的Divya M. Chari博士在本文中首先指出皮质类固醇疗法延缓中枢神经系统髓鞘再生过程的机制,接着表示皮质类固醇因对再生过程中相关基因的影响进而参与髓鞘再生过程,最后展望了将来皮质类固醇疗法对髓鞘发生的临床应用,即它可以协助鉴定药物标靶进而促进有效的髓鞘化和轴突保留,并且会给现存的神经系统治疗剂的改进带来启发或提供药物研发的新方向。

Abstract:

CS therapy is widely used in the treatment of Multiple Sclerosis (MS) and spinal cord injury. However, several reports have raised serious concerns regarding the adverse neurological consequences of CS use, including significantly delaying the production of new myelin (re-myelination) around axons in adult animal models following induction of experimental myelin loss (demyelination) in the central nervous system (CNS). Dr. Divya M. Chari from Keele University School of Medicine firstly elucidate the specific mechanisms underlying the adverse consequences of CS use, then points out the biological role of myelin and process of myelin genesis, lastly she demonstrates the future directions for CS therapy in myelin genesis, and considers information gained from such research can aid in the identification of factors underpinning remyelination failure and hence nerve fibre damage and repair. It can also assist in the identification of pharmacological targets to promote effective myelination for axon preservation, in turn leading to the development of better classes of therapeutic agents or to refinements to existing treatment regimens in neurological practice.